Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026)

Sarepta Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$204.8 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 67.35% year-over-year to -$204.8 million; the TTM figure through Mar 2026 stood at $114.9 million (up 116.52% YoY), while the FY2025 annual figure was -$307.5 million, up 10.3% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$204.8 million, down from $127.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $229.5 million in Q2 2025, with the low at -$627.1 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$100.4 million (2022), against an average of -$105.2 million.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 218.27% in 2022, then jumped 1713.64% in 2025.
• Sarepta Therapeutics' Free Cash Flow stood at -$100.4 million in 2022, then increased by 26.57% to -$73.7 million in 2023, then jumped by 173.23% to $54.0 million in 2024, then soared by 136.48% to $127.6 million in 2025, then plunged by 260.45% to -$204.8 million in 2026.
• Business Quant data shows SRPT's Free Cash Flow at -$204.8 million in Q1 2026, $127.6 million in Q4 2025, and -$37.5 million in Q3 2025.